A Minnesota jury awarded a woman more than $65 million on Friday after she claimed that lifetime use of Johnson and Johnson baby powder contributed to her cancer. The woman claimed the talcum product exposed her to asbast and that contributed to her developing a lung cancer caused primarily by exposure to the carcinogen. Johnson and Johnson for its part says the powder does not contain asbestous that it will appeal the ruling.The product was taken off shelves in 2020. ...

The announcement is scheduled for 1 p.m. ET at the White House. AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among major drugmakers expected to announce deals to cut ‌prices on some ‌medicines, according to sources familiar with the matter. Swiss drugmakers In July, Trump sent letters to leaders of 17 major pharmaceutical companies, outlining how they should provide so-called most-favored-nation prices to the U.S. government's Medicaid health program for low-income people, and guarantee th ...

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

Core Points - A Minnesota jury awarded $65.5 million to a plaintiff after finding Johnson & Johnson liable for exposing her to asbestos through its talc products, contributing to her mesothelioma diagnosis [1][2] - The trial revealed that Johnson & Johnson marketed talc-based products despite knowing the risk of asbestos contamination, which is a known carcinogen [2][4] - This verdict is considered the largest asbestos-related verdict in Minnesota's history, covering both economic and non-economic losses [5] Company Accountability - The case emphasized the need for accountability from Johnson & Johnson regarding its marketing practices and the safety of its products [4] - Evidence presented during the trial indicated that the company had knowledge for decades about the potential asbestos contamination in talc deposits but continued to promote its products as safe [4] Legal Context - The plaintiff, Anna Jean Houghton Carley, was diagnosed with mesothelioma in 2025, attributed to her exposure to Johnson & Johnson's baby powder during childhood [3] - The trial team included attorneys from Dean Omar Branham Shirley and Sieben Polk, P.A., who have previously secured significant verdicts against Johnson & Johnson related to talc products [5][6]

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the data center plays. These were the groups that saved you. We don’t talk about this migration much, but all you need to know is just to look at the stocks of Merck and Johnson & J ...

Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...

US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...

责任编辑：张俊 SF065 强生公司（JNJ）周五早盘上涨0.4%，该公司获得美国食品与药物管理局（FDA）批准：其 RYBREVANT FASPRO（amivantamab与透明质酸酶组合）可与lazertinib联用，用于一线治疗EGFR突变 非小细胞肺癌，实现5分钟皮下注射给药。 责任编辑：张俊 SF065 强生公司（JNJ）周五早盘上涨0.4%，该公司获得美国食品与药物管理局（FDA）批准：其 RYBREVANT FASPRO（amivantamab与透明质酸酶组合）可与lazertinib联用，用于一线治疗EGFR突变 非小细胞肺癌，实现5分钟皮下注射给药。 ...